Literature DB >> 23236557

Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.

Sakineh Abbasi1, Mina Rasouli, Mehrnaz Nouri, Samira Kalbasi.   

Abstract

Genetic mutations in premalignant breast lesions may have a role in malignancy progression or influence the behavior of subsequent disease. A point mutation in estrogen receptor-α (ER-α) as A908G (Lys303→Arg) was originally involved to hypersensitive to estrogen breast hyperplasia. We detected this mutation among Iranian women with invasive breast cancer. A population-based case-control study was conducted in 150 newly diagnosed invasive breast cancer and 147 healthy control individuals controls to screen for presence of the ER-α A908G mutation by using single-strand conformation polymorphism (SSCP) analysis and 33Pcycle DNA sequencing. We detected the 10.7% ER-α A908G mutation in the form of heterozygote genotype only among cancer patients (χ(2)=22.752, P=0.00). The allelic frequency of mutant allele AGG in codon 303 was significantly (χ(2)=29.709, P=0.001) higher in patients with the family history of breast cancer (28.9%) than those without the family history of breast cancer (1.9%). Our data suggest that ER-α codon 303 mutation is correlated with various aspects of breast cancer in Iran. ER-α genotype might represent a surrogate marker for predicting breast cancer developing later in life.

Entities:  

Keywords:  Breast cancer; PCR-SSCP; estrogen receptor; lymph node metastasis; mutation

Year:  2012        PMID: 23236557      PMCID: PMC3515972     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  38 in total

Review 1.  The role of estrogen receptors in breast cancer metastasis.

Authors:  S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

2.  Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells.

Authors:  Kwang Won Jeong; Rajas Chodankar; Daniel J Purcell; Danielle Bittencourt; Michael R Stallcup
Journal:  Mol Endocrinol       Date:  2012-04-27

3.  Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.

Authors:  Kathleen Conway; Sharon N Edmiston; Lisa Cui; S Scott Drouin; Jingzhong Pang; Mei He; Chiu-Kit Tse; Joseph Geradts; Lynn Dressler; Edison T Liu; Robert Millikan; Beth Newman
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

4.  Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis.

Authors:  André Vasconcelos; Rui Medeiros; Isabel Veiga; Deolinda Pereira; Susana Carrilho; Carlos Palmeira; Cândida Azevedo; Carlos S Lopes
Journal:  Breast J       Date:  2002 Jul-Aug       Impact factor: 2.431

5.  A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Authors:  Matthew H Herynk; Torsten Hopp; Yukun Cui; Airu Niu; Arnoldo Corona-Rodriguez; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2009-10-20       Impact factor: 4.872

6.  Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.

Authors:  Ines Barone; Yukun Cui; Matthew H Herynk; Arnoldo Corona-Rodriguez; Cinzia Giordano; Jennifer Selever; Amanda Beyer; Sebastiano Andò; Suzanne A W Fuqua
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

7.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

8.  PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

Authors:  Magdalena Cizkova; Aurélie Susini; Sophie Vacher; Géraldine Cizeron-Clairac; Catherine Andrieu; Keltouma Driouch; Emmanuelle Fourme; Rosette Lidereau; Ivan Bièche
Journal:  Breast Cancer Res       Date:  2012-02-13       Impact factor: 6.466

9.  Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation.

Authors:  Kathleen Conway; Eloise Parrish; Sharon N Edmiston; Dawn Tolbert; Chiu-Kit Tse; Patricia Moorman; Beth Newman; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  ESR1 and EGF genetic variation in relation to breast cancer risk and survival.

Authors:  Kristjana Einarsdóttir; Hatef Darabi; Yi Li; Yen Ling Low; Yu Qing Li; Carine Bonnard; Arvid Sjölander; Kamila Czene; Sara Wedrén; Edison T Liu; Per Hall; Keith Humphreys; Jianjun Liu
Journal:  Breast Cancer Res       Date:  2008-02-14       Impact factor: 6.466

View more
  13 in total

Review 1.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Authors:  Rinath Jeselsohn; Gilles Buchwalter; Carmine De Angelis; Myles Brown; Rachel Schiff
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

Review 2.  Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight.

Authors:  Suzanne A W Fuqua; Guowei Gu; Yassine Rechoum
Journal:  Breast Cancer Res Treat       Date:  2014-02-01       Impact factor: 4.872

Review 3.  The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.

Authors:  Sasha M Pejerrey; Derek Dustin; Jin-Ah Kim; Guowei Gu; Yassine Rechoum; Suzanne A W Fuqua
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

4.  Inter-Individual Variation in Response to Estrogen in Human Breast Explants.

Authors:  Karen A Dunphy; Amye L Black; Amy L Roberts; Aman Sharma; Zida Li; Sneha Suresh; Eva P Browne; Kathleen F Arcaro; Jennifer Ser-Dolansky; Carol Bigelow; Melissa A Troester; Sallie S Schneider; Grace Makari-Judson; Giovanna M Crisi; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-03-09       Impact factor: 2.673

5.  Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Authors:  Peilu Wang; Amir Bahreini; Rekha Gyanchandani; Peter C Lucas; Ryan J Hartmaier; Rebecca J Watters; Amruth R Jonnalagadda; Humberto E Trejo Bittar; Aaron Berg; Ronald L Hamilton; Brenda F Kurland; Kurt R Weiss; Aju Mathew; Jose Pablo Leone; Nancy E Davidson; Marina N Nikiforova; Adam M Brufsky; Tadeu F Ambros; Andrew M Stern; Shannon L Puhalla; Adrian V Lee; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531

6.  G9a-mediated methylation of ERα links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression.

Authors:  Xi Zhang; Danni Peng; Yuanxin Xi; Chao Yuan; Cari A Sagum; Brianna J Klein; Kaori Tanaka; Hong Wen; Tatiana G Kutateladze; Wei Li; Mark T Bedford; Xiaobing Shi
Journal:  Nat Commun       Date:  2016-03-10       Impact factor: 14.919

7.  A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population.

Authors:  Sakineh Abbasi; Mina Rasouli
Journal:  Mol Med Rep       Date:  2017-04-20       Impact factor: 2.952

Review 8.  Genetic and molecular biology of breast cancer among Iranian patients.

Authors:  Meysam Moghbeli
Journal:  J Transl Med       Date:  2019-07-08       Impact factor: 5.531

9.  Detection of three closely located single nucleotide polymorphisms in the EAAT2 promoter: comparison of single-strand conformational polymorphism (SSCP), pyrosequencing and Sanger sequencing.

Authors:  Shavanthi Rajatileka; Karen Luyt; Maggie Williams; David Harding; David Odd; Elek Molnár; Anikó Váradi
Journal:  BMC Genet       Date:  2014-07-05       Impact factor: 2.797

Review 10.  Tamoxifen Resistance: Emerging Molecular Targets.

Authors:  Milena Rondón-Lagos; Victoria E Villegas; Nelson Rangel; Magda Carolina Sánchez; Peter G Zaphiropoulos
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.